FAVIRAB

Main information

  • Trade name:
  • FAVIRAB Solution for injection 1000-2000IU/5ML
  • Dosage:
  • 1000-2000IU/5ML
  • Pharmaceutical form:
  • Solution for injection
  • Administration route:
  • Intramuscular use
  • Units in package:
  • 1X5ML Ampoule
  • Prescription type:
  • with prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • FAVIRAB Solution for injection 1000-2000IU/5ML
    Czech Republic
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • THE SERUM AGAINST RABIES
  • Product summary:
  • FAVIRAB

Other information

Status

  • Source:
  • SUKL - Státní ústav pro kontrolu léčiv
  • Authorization number:
  • F - specific therapeutic programme
  • Last update:
  • 04-04-2018

27-8-2018

Several unauthorized products seized from Vitality Health Foods in Drayton Valley, AB, may pose serious health risks

Several unauthorized products seized from Vitality Health Foods in Drayton Valley, AB, may pose serious health risks

Health Canada is advising Canadians that several unauthorized products seized from Vitality Health Foods in Drayton Valley, AB, may pose serious health risks. The 11products include vitamins, dietary supplements, workout supplements and decongestants. Seized products were labelled to contain various ingredients, including prescription drugs and controlled substances.

Health Canada

20-6-2018

Public Notification: AB Slim contains hidden drug ingredients

Public Notification: AB Slim contains hidden drug ingredients

The Food and Drug Administration is advising consumers not to purchase or use AB Slim, a product promoted for weight loss. This product was identified by FDA during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

29-5-2018

EU/3/18/2021 (Chemo Research S.L.)

EU/3/18/2021 (Chemo Research S.L.)

EU/3/18/2021 (Active substance: Equine immunoglobulin F(ab')2 fragments targeting Shiga toxin) - Orphan designation - Commission Decision (2018)3388 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/248/17

Europe -DG Health and Food Safety